Phase 4 IOP Signals Associated With ILUVIEN®

Summary

This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.

Timeline

Start

2015-05-06

Primary completion

2020-07-29

Completion

2020-07-31

Publications

• Eichenbaum D, Gonzalez VH, Roth D, Fortun J, Radcliffe NM, Cutino A, Kasper J, Coughlin BA, Arevalo JF. Ocular, Visual, and Anatomical Outcomes in Eyes Requiring Incisional Intraocular Pressure-Lowering Surgery Following the 0.19-mg Fluocinolone Acetonide Intravitreal Implant. Ophthalmic Surg Lasers Imaging Retina. 2024 Jan;55(1):22-23. doi: 10.3928/23258160-20231109-02. Epub 2024 Jan 1.
• Mansour SE, Kiernan DF, Roth DB, Eichenbaum D, Holekamp NM, Kaba S, Werts E. Two-year interim safety results of the 0.2 microg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Br J Ophthalmol. 2021 Mar;105(3):414-419. doi: 10.1136/bjophthalmol-2020-315984. Epub 2020 May 27.

Drugs

Indications